Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Nelfinavir
- Accession Number
- DB00220 (APRD00003)
- Type
- Small Molecule
- Groups
- Approved
- Description
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Structure
Structure for DB00220 (Nelfinavir)
- Synonyms
- Not Available
- External IDs
- AG1343
- Product Ingredients
Ingredient UNII CAS InChI Key Nelfinavir mesylate 98D603VP8V 159989-65-8 NQHXCOAXSHGTIA-SKXNDZRYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Viracept Tablet, film coated 625 mg/1 Oral Remedy Repack 2013-03-27 2016-03-11 US 
Viracept Tablet, film coated 625 mg/1 Oral Agouron Pharmaceuticals 2003-04-30 Not applicable US Viracept Tablet 625 mg Oral Pfizer 2004-08-11 Not applicable Canada 
Viracept Tablet, film coated 625 mg/1 Oral State of Florida DOH Central Pharmacy 2009-07-01 Not applicable US Viracept Tablet, film coated 250 mg/1 Oral Agouron Pharmaceuticals 1997-03-14 Not applicable US Viracept Tablet, film coated 250 mg/1 Oral H.J. Harkins Company 1997-03-14 Not applicable US 
Viracept Tablet, film coated 250 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 1997-03-14 Not applicable US Viracept Powder 50 mg/g Oral Agouron Pharmaceuticals 1997-03-14 2016-02-26 US Viracept -250mg Tablet 250 mg Oral Pfizer 1998-09-21 Not applicable Canada Viracept -50mg Powder 50 mg Oral Pfizer 1998-09-21 Not applicable Canada - Categories
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiinfectives for Systemic Use
- Antiviral Agents
- Antivirals for Systemic Use
- BCRP/ABCG2 Inhibitors
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 CYP2B6 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors (moderate)
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Inhibitors (strong)
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A7 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Direct Acting Antivirals
- Enzyme Inhibitors
- HIV Protease Inhibitors
- Hyperglycemia-Associated Agents
- Isoquinolines
- P-glycoprotein/ABCB1 Inducers
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- Protease Inhibitors
- QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)
- UNII
- HO3OGH5D7I
- CAS number
- 159989-64-7
- Weight
- Average: 567.782
Monoisotopic: 567.313077633 - Chemical Formula
- C32H45N3O4S
- InChI Key
- QAGYKUNXZHXKMR-HKWSIXNMSA-N
- InChI
- InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1
- IUPAC Name
- (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide
- SMILES
- [H][[email protected]@]12CCCC[[email protected]]1([H])CN(C[[email protected]@H](O)[[email protected]](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[[email protected]@H](C2)C(=O)NC(C)(C)C
Pharmacology
- Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
- Structured Indications
- Pharmacodynamics
Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
- Mechanism of action
Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Target Actions Organism AHIV-1 protease inhibitorHuman immunodeficiency virus - Absorption
Well absorbed following oral administration.
- Volume of distribution
- 2 to 7 L/kg
- Protein binding
>98%
- Metabolism
Primarily hepatic via cytochrome P450 (CYP450) enzymes. CYP3A and CYP2C19 appear to be the predominant enzymes that metabolize nelfinavir in humans. One major and several minor metabolites are found in plasma; the major oxidative metabolite has in vitro antiviral activity comparable to that of the parent drug.
- Route of elimination
The terminal half-life in plasma was typically 3.5 to 5 hours. The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.
- Half life
3.5 - 5 hours
- Clearance
- Not Available
- Toxicity
Oral LD50 is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
- Affected organisms
- Human Immunodeficiency Virus
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nelfinavir. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir. Experimental, Illicit 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Nelfinavir. Investigational 5-androstenedione The serum concentration of 5-androstenedione can be increased when it is combined with Nelfinavir. Experimental, Illicit Abacavir The serum concentration of Abacavir can be decreased when it is combined with Nelfinavir. Approved, Investigational Abemaciclib The risk or severity of adverse effects can be increased when Nelfinavir is combined with Abemaciclib. Approved, Investigational Abiraterone The metabolism of Abiraterone can be decreased when combined with Nelfinavir. Approved Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Nelfinavir. Approved, Investigational Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Nelfinavir. Approved, Investigational Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Nelfinavir. Approved Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nelfinavir. Approved, Investigational, Withdrawn Adinazolam The metabolism of Adinazolam can be decreased when combined with Nelfinavir. Approved Afatinib The serum concentration of Afatinib can be decreased when it is combined with Nelfinavir. Approved AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Nelfinavir. Experimental, Investigational Albendazole The metabolism of Albendazole can be decreased when combined with Nelfinavir. Approved, Vet Approved Alclometasone The metabolism of Alclometasone can be decreased when combined with Nelfinavir. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Nelfinavir. Experimental, Investigational Alfentanil The metabolism of Alfentanil can be decreased when combined with Nelfinavir. Approved, Illicit Alfuzosin The serum concentration of Alfuzosin can be increased when it is combined with Nelfinavir. Approved, Investigational Aliskiren The metabolism of Aliskiren can be decreased when combined with Nelfinavir. Approved, Investigational Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Nelfinavir. Investigational Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Nelfinavir. Approved Almotriptan The serum concentration of Almotriptan can be increased when it is combined with Nelfinavir. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Nelfinavir. Approved Alosetron The serum concentration of Alosetron can be increased when it is combined with Nelfinavir. Approved, Withdrawn alpha-Tocopherol acetate The metabolism of alpha-Tocopherol acetate can be decreased when combined with Nelfinavir. Approved Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Nelfinavir. Approved, Illicit, Investigational Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Nelfinavir. Approved, Investigational Ambroxol The metabolism of Ambroxol can be decreased when combined with Nelfinavir. Approved, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nelfinavir. Experimental, Investigational Amcinonide The serum concentration of Amcinonide can be increased when it is combined with Nelfinavir. Approved Amineptine The serum concentration of Amineptine can be increased when it is combined with Nelfinavir. Illicit, Withdrawn Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Nelfinavir. Approved, Withdrawn Aminophylline The metabolism of Aminophylline can be decreased when combined with Nelfinavir. Approved Amiodarone The serum concentration of Amiodarone can be increased when it is combined with Nelfinavir. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Nelfinavir. Approved Amlodipine The metabolism of Amlodipine can be decreased when combined with Nelfinavir. Approved Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Nelfinavir. Approved Amoxicillin The metabolism of Amoxicillin can be decreased when combined with Nelfinavir. Approved, Vet Approved Amprenavir The metabolism of Amprenavir can be decreased when combined with Nelfinavir. Approved, Investigational Anagrelide Nelfinavir may increase the QTc-prolonging activities of Anagrelide. Approved Androstenedione The serum concentration of Androstenedione can be increased when it is combined with Nelfinavir. Experimental, Illicit Anecortave The serum concentration of Anecortave can be increased when it is combined with Nelfinavir. Investigational anecortave acetate The serum concentration of anecortave acetate can be increased when it is combined with Nelfinavir. Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Nelfinavir. Approved, Investigational Apalutamide The serum concentration of Apalutamide can be increased when it is combined with Nelfinavir. Approved, Investigational Apixaban The serum concentration of Apixaban can be increased when it is combined with Nelfinavir. Approved Apremilast The metabolism of Apremilast can be decreased when combined with Nelfinavir. Approved, Investigational Aprepitant The serum concentration of Nelfinavir can be increased when it is combined with Aprepitant. Approved, Investigational Arformoterol The metabolism of Arformoterol can be decreased when combined with Nelfinavir. Approved, Investigational Argatroban The metabolism of Argatroban can be decreased when combined with Nelfinavir. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir. Approved, Investigational Armodafinil The metabolism of Nelfinavir can be decreased when combined with Armodafinil. Approved, Investigational Arsenic trioxide Nelfinavir may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether The metabolism of Artemether can be decreased when combined with Nelfinavir. Approved Asenapine The serum concentration of Nelfinavir can be decreased when it is combined with Asenapine. Approved Astemizole The serum concentration of Astemizole can be increased when it is combined with Nelfinavir. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Nelfinavir. Approved, Investigational, Withdrawn Atamestane The serum concentration of Atamestane can be increased when it is combined with Nelfinavir. Investigational Atazanavir The metabolism of Atazanavir can be decreased when combined with Nelfinavir. Approved, Investigational Atomoxetine The metabolism of Nelfinavir can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Nelfinavir is combined with Atorvastatin. Approved Avanafil The serum concentration of Avanafil can be increased when it is combined with Nelfinavir. Approved Axitinib The serum concentration of Axitinib can be increased when it is combined with Nelfinavir. Approved, Investigational Azelastine The metabolism of Azelastine can be decreased when combined with Nelfinavir. Approved Azithromycin The serum concentration of Azithromycin can be increased when it is combined with Nelfinavir. Approved Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Nelfinavir. Investigational Banoxantrone The metabolism of Banoxantrone can be decreased when combined with Nelfinavir. Investigational Baricitinib The metabolism of Baricitinib can be decreased when combined with Nelfinavir. Approved, Investigational Barnidipine The serum concentration of Barnidipine can be increased when it is combined with Nelfinavir. Approved Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nelfinavir. Approved, Investigational Bedaquiline The serum concentration of Bedaquiline can be increased when it is combined with Nelfinavir. Approved Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Nelfinavir. Investigational Benidipine The metabolism of Benidipine can be decreased when combined with Nelfinavir. Approved, Investigational Benzatropine The metabolism of Benzatropine can be decreased when combined with Nelfinavir. Approved Benzphetamine The metabolism of Benzphetamine can be decreased when combined with Nelfinavir. Approved, Illicit Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Nelfinavir. Approved Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Bexarotene The metabolism of Bexarotene can be decreased when combined with Nelfinavir. Approved, Investigational Bezafibrate The metabolism of Bezafibrate can be decreased when combined with Nelfinavir. Approved, Investigational Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Nelfinavir. Approved Bictegravir The metabolism of Bictegravir can be decreased when combined with Nelfinavir. Approved, Investigational Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Nelfinavir. Approved Blonanserin The metabolism of Blonanserin can be decreased when combined with Nelfinavir. Approved, Investigational Boceprevir The serum concentration of Nelfinavir can be decreased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Nelfinavir. Approved, Investigational Bosentan The serum concentration of Bosentan can be increased when it is combined with Nelfinavir. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Nelfinavir. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Nelfinavir. Approved, Investigational Brigatinib The serum concentration of Brigatinib can be increased when it is combined with Nelfinavir. Approved, Investigational Brinzolamide The serum concentration of Brinzolamide can be increased when it is combined with Nelfinavir. Approved Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Nelfinavir. Approved, Investigational Bromazepam The metabolism of Bromazepam can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nelfinavir. Approved, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Nelfinavir. Approved Budesonide The serum concentration of Budesonide can be increased when it is combined with Nelfinavir. Approved Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Nelfinavir. Investigational, Withdrawn Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Nelfinavir. Approved, Investigational Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Bupropion can be decreased when combined with Nelfinavir. Approved Buspirone The metabolism of Buspirone can be decreased when combined with Nelfinavir. Approved, Investigational Busulfan The metabolism of Busulfan can be decreased when combined with Nelfinavir. Approved, Investigational Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Nelfinavir. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Nelfinavir. Approved Cabozantinib The serum concentration of Cabozantinib can be increased when it is combined with Nelfinavir. Approved, Investigational Caffeine The metabolism of Caffeine can be decreased when combined with Nelfinavir. Approved Calcitriol The metabolism of Calcitriol can be decreased when combined with Nelfinavir. Approved, Nutraceutical Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Nelfinavir. Approved Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Nelfinavir. Approved, Investigational Carbamazepine The metabolism of Nelfinavir can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Nelfinavir. Approved Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Nelfinavir. Experimental Cariprazine The metabolism of Cariprazine can be decreased when combined with Nelfinavir. Approved, Investigational Carisoprodol The metabolism of Carisoprodol can be decreased when combined with Nelfinavir. Approved Carvedilol The metabolism of Carvedilol can be decreased when combined with Nelfinavir. Approved, Investigational Castanospermine The therapeutic efficacy of Castanospermine can be decreased when used in combination with Nelfinavir. Experimental Celecoxib The metabolism of Celecoxib can be decreased when combined with Nelfinavir. Approved, Investigational Celiprolol The metabolism of Celiprolol can be decreased when combined with Nelfinavir. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Nelfinavir. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Nelfinavir. Approved, Withdrawn Cevimeline The metabolism of Cevimeline can be decreased when combined with Nelfinavir. Approved Chenodeoxycholic acid The metabolism of Chenodeoxycholic acid can be decreased when combined with Nelfinavir. Approved Chloramphenicol The metabolism of Nelfinavir can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational Chloroquine The metabolism of Chloroquine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Chlorotrianisene The serum concentration of Chlorotrianisene can be decreased when it is combined with Nelfinavir. Investigational, Withdrawn Chlorphenamine The metabolism of Chlorphenamine can be decreased when combined with Nelfinavir. Approved Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Nelfinavir. Approved, Investigational Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Nelfinavir. Approved Cholecalciferol The metabolism of Cholecalciferol can be decreased when combined with Nelfinavir. Approved, Nutraceutical Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Nelfinavir. Approved, Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nelfinavir. Experimental Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Nelfinavir. Approved, Investigational Cimetidine The serum concentration of Nelfinavir can be decreased when it is combined with Cimetidine. Approved, Investigational Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Nelfinavir. Approved Ciprofloxacin Nelfinavir may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride The metabolism of Cisapride can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Citalopram The serum concentration of Citalopram can be increased when it is combined with Nelfinavir. Approved Clarithromycin The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nelfinavir. Approved Clemastine The metabolism of Nelfinavir can be decreased when combined with Clemastine. Approved, Investigational Clindamycin The metabolism of Clindamycin can be decreased when combined with Nelfinavir. Approved, Vet Approved Clobazam The metabolism of Clobazam can be decreased when combined with Nelfinavir. Approved, Illicit Clobetasol The serum concentration of Clobetasol can be increased when it is combined with Nelfinavir. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be increased when it is combined with Nelfinavir. Approved Clobetasone The serum concentration of Clobetasone can be increased when it is combined with Nelfinavir. Approved Clocortolone The serum concentration of Clocortolone can be increased when it is combined with Nelfinavir. Approved Clofazimine The metabolism of Clofazimine can be decreased when combined with Nelfinavir. Approved, Investigational Clofibrate The metabolism of Clofibrate can be decreased when combined with Nelfinavir. Approved, Investigational clomethiazole The metabolism of clomethiazole can be decreased when combined with Nelfinavir. Investigational Clomipramine The metabolism of Clomipramine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Clonazepam The metabolism of Clonazepam can be decreased when combined with Nelfinavir. Approved, Illicit Clonidine The metabolism of Clonidine can be decreased when combined with Nelfinavir. Approved Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Clorazepate The metabolism of Clorazepate can be decreased when combined with Nelfinavir. Approved, Illicit Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Nelfinavir. Approved, Illicit Clotrimazole The metabolism of Nelfinavir can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Nelfinavir. Approved Cobicistat The metabolism of Nelfinavir can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Nelfinavir. Approved, Investigational Cocaine The metabolism of Cocaine can be decreased when combined with Nelfinavir. Approved, Illicit Codeine The metabolism of Codeine can be decreased when combined with Nelfinavir. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Nelfinavir. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Nelfinavir. Approved, Investigational Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Nelfinavir. Approved Copanlisib The metabolism of Copanlisib can be decreased when combined with Nelfinavir. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Nelfinavir. Investigational Corticosterone The serum concentration of Corticosterone can be increased when it is combined with Nelfinavir. Experimental Cortisone acetate The metabolism of Cortisone acetate can be decreased when combined with Nelfinavir. Approved, Investigational Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Nelfinavir. Approved Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir. Approved Cyclophosphamide The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Cytarabine The metabolism of Cytarabine can be decreased when combined with Nelfinavir. Approved, Investigational Dabigatran etexilate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir. Approved Dabrafenib The serum concentration of Nelfinavir can be decreased when it is combined with Dabrafenib. Approved, Investigational Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Nelfinavir. Approved, Investigational Dantrolene The metabolism of Dantrolene can be decreased when combined with Nelfinavir. Approved, Investigational Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Nelfinavir. Approved Dapoxetine The serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir. Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Nelfinavir. Approved, Investigational Darifenacin The metabolism of Darifenacin can be decreased when combined with Nelfinavir. Approved, Investigational Darunavir The metabolism of Darunavir can be decreased when combined with Nelfinavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Nelfinavir. Approved Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Nelfinavir. Approved, Investigational Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Nelfinavir. Approved Deferasirox The serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The metabolism of Deflazacort can be decreased when combined with Nelfinavir. Approved, Investigational Delamanid Nelfinavir may increase the QTc-prolonging activities of Delamanid. Approved, Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Nelfinavir. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Nelfinavir. Investigational Desipramine The serum concentration of Desipramine can be increased when it is combined with Nelfinavir. Approved, Investigational Desogestrel The serum concentration of Desogestrel can be decreased when it is combined with Nelfinavir. Approved Desonide The serum concentration of Desonide can be increased when it is combined with Nelfinavir. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be increased when it is combined with Nelfinavir. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Nelfinavir. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nelfinavir. Experimental, Vet Approved Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir. Approved, Investigational Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Nelfinavir. Approved, Investigational Dexamethasone The metabolism of Dexamethasone can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Nelfinavir. Vet Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Nelfinavir. Approved Dexlansoprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Dexlansoprazole resulting in a loss in efficacy. Approved, Investigational Dexrabeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Dexrabeprazole resulting in a loss in efficacy. Experimental Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Nelfinavir. Approved Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational, Withdrawn Diazepam The metabolism of Diazepam can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational, Vet Approved Dibenzepin The serum concentration of Dibenzepin can be increased when it is combined with Nelfinavir. Experimental Diclofenac The metabolism of Diclofenac can be decreased when combined with Nelfinavir. Approved, Vet Approved Dienestrol The serum concentration of Dienestrol can be decreased when it is combined with Nelfinavir. Approved, Investigational Dienogest The serum concentration of Dienogest can be decreased when it is combined with Nelfinavir. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Nelfinavir. Approved, Investigational Diflorasone The serum concentration of Diflorasone can be increased when it is combined with Nelfinavir. Approved Difluocortolone The serum concentration of Difluocortolone can be increased when it is combined with Nelfinavir. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be increased when it is combined with Nelfinavir. Approved Digitoxin The metabolism of Digitoxin can be decreased when combined with Nelfinavir. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Nelfinavir. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir. Approved, Illicit Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nelfinavir. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nelfinavir. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nelfinavir. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nelfinavir. Approved, Investigational Diltiazem The metabolism of Diltiazem can be decreased when combined with Nelfinavir. Approved, Investigational Diphenhydramine The metabolism of Diphenhydramine can be decreased when combined with Nelfinavir. Approved, Investigational Disopyramide The metabolism of Disopyramide can be decreased when combined with Nelfinavir. Approved Disulfiram The metabolism of Disulfiram can be decreased when combined with Nelfinavir. Approved Docetaxel The metabolism of Docetaxel can be decreased when combined with Nelfinavir. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Nelfinavir. Approved, Investigational Dolasetron The metabolism of Dolasetron can be decreased when combined with Nelfinavir. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Nelfinavir. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Nelfinavir. Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Nelfinavir. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Nelfinavir. Approved Doxazosin The metabolism of Doxazosin can be decreased when combined with Nelfinavir. Approved Doxepin The serum concentration of Nelfinavir can be decreased when it is combined with Doxepin. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Nelfinavir. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Nelfinavir. Approved, Investigational Doxycycline The metabolism of Nelfinavir can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Nelfinavir. Approved, Illicit Dronedarone The serum concentration of Dronedarone can be increased when it is combined with Nelfinavir. Approved Droperidol Nelfinavir may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Drospirenone The serum concentration of Drospirenone can be decreased when it is combined with Nelfinavir. Approved Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nelfinavir. Approved, Investigational Dutasteride The serum concentration of Dutasteride can be increased when it is combined with Nelfinavir. Approved, Investigational Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Nelfinavir. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Nelfinavir. Approved Efavirenz The metabolism of Efavirenz can be decreased when combined with Nelfinavir. Approved, Investigational Elbasvir The metabolism of Elbasvir can be decreased when combined with Nelfinavir. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Nelfinavir. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Nelfinavir. Approved Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Nelfinavir. Approved Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir. Approved Enalapril The metabolism of Enalapril can be decreased when combined with Nelfinavir. Approved, Vet Approved Enasidenib The metabolism of Enasidenib can be decreased when combined with Nelfinavir. Approved, Investigational Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Nelfinavir. Approved, Investigational Enzalutamide The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide. Approved Epinastine The serum concentration of Nelfinavir can be decreased when it is combined with Epinastine. Approved, Investigational Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Nelfinavir. Approved Equilenin The serum concentration of Equilenin can be increased when it is combined with Nelfinavir. Experimental Equilin The serum concentration of Equilin can be increased when it is combined with Nelfinavir. Approved Ergocalciferol The metabolism of Ergocalciferol can be decreased when combined with Nelfinavir. Approved, Nutraceutical Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Nelfinavir. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Nelfinavir. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Nelfinavir. Approved, Investigational Erythromycin The metabolism of Erythromycin can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Escitalopram The metabolism of Escitalopram can be decreased when combined with Nelfinavir. Approved, Investigational Eslicarbazepine acetate The metabolism of Nelfinavir can be decreased when combined with Eslicarbazepine acetate. Approved Esmirtazapine The serum concentration of Esmirtazapine can be increased when it is combined with Nelfinavir. Investigational Esomeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy. Approved, Investigational Estazolam The serum concentration of Estazolam can be increased when it is combined with Nelfinavir. Approved, Illicit Estradiol The metabolism of Estradiol can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estramustine The metabolism of Estramustine can be decreased when combined with Nelfinavir. Approved, Investigational Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Nelfinavir. Approved Estrone The metabolism of Estrone can be decreased when combined with Nelfinavir. Approved Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Nelfinavir. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Nelfinavir. Approved, Investigational Ethanol The metabolism of Ethanol can be decreased when combined with Nelfinavir. Approved Ethinyl Estradiol The metabolism of Ethinyl Estradiol can be decreased when combined with Nelfinavir. Approved Ethosuximide The metabolism of Ethosuximide can be decreased when combined with Nelfinavir. Approved Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Nelfinavir. Approved, Illicit Ethynodiol diacetate The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nelfinavir. Approved Etizolam The serum concentration of Etizolam can be increased when it is combined with Nelfinavir. Approved Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Nelfinavir. Approved, Investigational Etoposide The metabolism of Etoposide can be decreased when combined with Nelfinavir. Approved Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Nelfinavir. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Nelfinavir. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Nelfinavir. Approved Exemestane The metabolism of Exemestane can be decreased when combined with Nelfinavir. Approved, Investigational Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Nelfinavir. Approved, Investigational Famciclovir The metabolism of Famciclovir can be decreased when combined with Nelfinavir. Approved, Investigational Famotidine The serum concentration of Nelfinavir can be decreased when it is combined with Famotidine. Approved Felbamate The metabolism of Felbamate can be decreased when combined with Nelfinavir. Approved Felodipine The metabolism of Felodipine can be decreased when combined with Nelfinavir. Approved, Investigational Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Nelfinavir. Approved Fentanyl The serum concentration of Fentanyl can be increased when it is combined with Nelfinavir. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir. Approved Finasteride The metabolism of Finasteride can be decreased when combined with Nelfinavir. Approved Fingolimod The metabolism of Fingolimod can be decreased when combined with Nelfinavir. Approved, Investigational Flecainide Nelfinavir may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Nelfinavir. Approved, Investigational Fluasterone The serum concentration of Fluasterone can be increased when it is combined with Nelfinavir. Investigational Fluconazole The metabolism of Nelfinavir can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone The serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Flunisolide The metabolism of Flunisolide can be decreased when combined with Nelfinavir. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Nelfinavir. Approved, Illicit Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be increased when it is combined with Nelfinavir. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be increased when it is combined with Nelfinavir. Approved, Withdrawn Fluorometholone The metabolism of Fluorometholone can be decreased when combined with Nelfinavir. Approved, Investigational Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Nelfinavir. Approved, Vet Approved Flupentixol Nelfinavir may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluprednidene The serum concentration of Fluprednidene can be increased when it is combined with Nelfinavir. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be increased when it is combined with Nelfinavir. Approved Flurandrenolide The serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir. Approved Flurazepam The metabolism of Flurazepam can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational Flutamide The metabolism of Flutamide can be decreased when combined with Nelfinavir. Approved, Investigational Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Nelfinavir. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be increased when it is combined with Nelfinavir. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Nelfinavir. Approved Fluvoxamine The metabolism of Nelfinavir can be decreased when combined with Fluvoxamine. Approved, Investigational Formestane The serum concentration of Formestane can be increased when it is combined with Nelfinavir. Approved, Investigational, Withdrawn Formoterol The metabolism of Formoterol can be decreased when combined with Nelfinavir. Approved, Investigational Fosamprenavir The metabolism of Fosamprenavir can be decreased when combined with Nelfinavir. Approved Fosaprepitant The serum concentration of Nelfinavir can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Nelfinavir can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Nelfinavir. Approved, Investigational Fusidic Acid The serum concentration of Nelfinavir can be increased when it is combined with Fusidic Acid. Approved, Investigational Gadobenic acid Nelfinavir may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Galantamine The metabolism of Galantamine can be decreased when combined with Nelfinavir. Approved Garlic The serum concentration of Nelfinavir can be decreased when it is combined with Garlic. Approved Gefitinib The metabolism of Gefitinib can be decreased when combined with Nelfinavir. Approved, Investigational Gemfibrozil The metabolism of Gemfibrozil can be decreased when combined with Nelfinavir. Approved Gemifloxacin Nelfinavir may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gestodene The serum concentration of Gestodene can be decreased when it is combined with Nelfinavir. Approved, Investigational Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Nelfinavir. Investigational, Withdrawn Gliclazide The metabolism of Gliclazide can be decreased when combined with Nelfinavir. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir. Approved Glipizide The metabolism of Glipizide can be decreased when combined with Nelfinavir. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Nelfinavir. Approved, Investigational Glucosamine The metabolism of Glucosamine can be decreased when combined with Nelfinavir. Approved, Investigational Glyburide The metabolism of Glyburide can be decreased when combined with Nelfinavir. Approved Goserelin Nelfinavir may increase the QTc-prolonging activities of Goserelin. Approved Granisetron The metabolism of Granisetron can be decreased when combined with Nelfinavir. Approved, Investigational Grazoprevir The metabolism of Grazoprevir can be decreased when combined with Nelfinavir. Approved Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Guanfacine The serum concentration of Guanfacine can be increased when it is combined with Nelfinavir. Approved, Investigational Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Nelfinavir. Investigational Halcinonide The serum concentration of Halcinonide can be increased when it is combined with Nelfinavir. Approved, Investigational, Withdrawn Halofantrine The serum concentration of Halofantrine can be increased when it is combined with Nelfinavir. Approved Haloperidol The metabolism of Haloperidol can be decreased when combined with Nelfinavir. Approved Halothane The metabolism of Halothane can be decreased when combined with Nelfinavir. Approved, Vet Approved HE3286 The serum concentration of HE3286 can be increased when it is combined with Nelfinavir. Investigational Hexestrol The serum concentration of Hexestrol can be decreased when it is combined with Nelfinavir. Withdrawn Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Nelfinavir. Approved Histamine The metabolism of Histamine can be decreased when combined with Nelfinavir. Approved, Investigational Hydrocodone The serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir. Approved, Illicit Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir. Approved, Vet Approved Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Nelfinavir. Approved, Illicit Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nelfinavir. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Nelfinavir. Approved Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Nelfinavir. Approved Ibutilide Nelfinavir may increase the QTc-prolonging activities of Ibutilide. Approved Icotinib The metabolism of Icotinib can be decreased when combined with Nelfinavir. Approved, Investigational Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Nelfinavir. Approved Ifosfamide The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Iloperidone The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir. Approved Imatinib The serum concentration of Imatinib can be increased when it is combined with Nelfinavir. Approved Imidafenacin The serum concentration of Imidafenacin can be increased when it is combined with Nelfinavir. Approved, Investigational Imipramine The metabolism of Imipramine can be decreased when combined with Nelfinavir. Approved Imiquimod The metabolism of Imiquimod can be decreased when combined with Nelfinavir. Approved, Investigational Indacaterol The metabolism of Indacaterol can be decreased when combined with Nelfinavir. Approved Indapamide The metabolism of Indapamide can be decreased when combined with Nelfinavir. Approved Indinavir The metabolism of Indinavir can be decreased when combined with Nelfinavir. Approved Indomethacin The metabolism of Indomethacin can be decreased when combined with Nelfinavir. Approved, Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nelfinavir. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nelfinavir. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nelfinavir. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nelfinavir. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Nelfinavir. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nelfinavir. Approved Ipratropium bromide The metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir. Approved Iprindole The serum concentration of Iprindole can be increased when it is combined with Nelfinavir. Experimental Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Nelfinavir. Approved, Investigational Isavuconazole The serum concentration of Isavuconazole can be increased when it is combined with Nelfinavir. Approved, Investigational Isavuconazonium The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nelfinavir. Approved, Investigational Isoniazid The metabolism of Nelfinavir can be decreased when combined with Isoniazid. Approved, Investigational Isosorbide Dinitrate The metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir. Approved, Investigational Isosorbide Mononitrate The metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir. Approved Isradipine The metabolism of Isradipine can be decreased when combined with Nelfinavir. Approved, Investigational Istaroxime The serum concentration of Istaroxime can be increased when it is combined with Nelfinavir. Investigational Itraconazole The metabolism of Itraconazole can be decreased when combined with Nelfinavir. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Nelfinavir. Approved Ivacaftor The serum concentration of Ivacaftor can be increased when it is combined with Nelfinavir. Approved Ivermectin The metabolism of Ivermectin can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Ixabepilone The serum concentration of Ixabepilone can be increased when it is combined with Nelfinavir. Approved, Investigational Ixazomib The metabolism of Ixazomib can be decreased when combined with Nelfinavir. Approved, Investigational Ketamine The metabolism of Ketamine can be decreased when combined with Nelfinavir. Approved, Vet Approved Ketazolam The metabolism of Ketazolam can be decreased when combined with Nelfinavir. Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Nelfinavir. Approved, Investigational Ketoconazole The metabolism of Ketoconazole can be decreased when combined with Nelfinavir. Approved, Investigational Lacidipine The serum concentration of Lacidipine can be increased when it is combined with Nelfinavir. Approved, Investigational Lacosamide The serum concentration of Lacosamide can be increased when it is combined with Nelfinavir. Approved Lansoprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy. Approved, Investigational Lapatinib The serum concentration of Lapatinib can be increased when it is combined with Nelfinavir. Approved, Investigational Laquinimod The metabolism of Laquinimod can be decreased when combined with Nelfinavir. Investigational Ledipasvir The serum concentration of Ledipasvir can be decreased when it is combined with Nelfinavir. Approved Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Nelfinavir. Approved Lenvatinib The metabolism of Lenvatinib can be decreased when combined with Nelfinavir. Approved, Investigational Lercanidipine The serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir. Approved, Investigational Letrozole The metabolism of Letrozole can be decreased when combined with Nelfinavir. Approved, Investigational Leuprolide Nelfinavir may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levobupivacaine The serum concentration of Levobupivacaine can be increased when it is combined with Nelfinavir. Approved, Investigational Levocetirizine The metabolism of Levocetirizine can be decreased when combined with Nelfinavir. Approved Levofloxacin Nelfinavir may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl Acetate The metabolism of Levomethadyl Acetate can be decreased when combined with Nelfinavir. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Nelfinavir. Approved, Investigational Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Nelfinavir. Approved, Investigational Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Nelfinavir. Approved Lidocaine The metabolism of Lidocaine can be decreased when combined with Nelfinavir. Approved, Vet Approved Linagliptin The serum concentration of Linagliptin can be decreased when it is combined with Nelfinavir. Approved Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Nelfinavir. Approved Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Nelfinavir. Approved, Investigational Lobeglitazone The metabolism of Nelfinavir can be decreased when combined with Lobeglitazone. Approved, Investigational Lofepramine The serum concentration of Lofepramine can be increased when it is combined with Nelfinavir. Experimental Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Nelfinavir. Approved, Investigational Loperamide The metabolism of Loperamide can be decreased when combined with Nelfinavir. Approved Lopinavir The serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir. Approved Loratadine The metabolism of Loratadine can be decreased when combined with Nelfinavir. Approved, Investigational Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Nelfinavir. Approved Lorpiprazole The serum concentration of Nelfinavir can be increased when it is combined with Lorpiprazole. Approved Losartan The metabolism of Losartan can be decreased when combined with Nelfinavir. Approved Loteprednol The serum concentration of Loteprednol can be increased when it is combined with Nelfinavir. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Nelfinavir. Approved, Investigational Luliconazole The serum concentration of Nelfinavir can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Nelfinavir can be decreased when it is combined with Lumacaftor. Approved Lumefantrine The serum concentration of Lumefantrine can be increased when it is combined with Nelfinavir. Approved Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Nelfinavir. Approved, Investigational Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir. Approved, Investigational Lynestrenol The serum concentration of Lynestrenol can be decreased when it is combined with Nelfinavir. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nelfinavir. Illicit, Investigational, Withdrawn Macimorelin The metabolism of Macimorelin can be decreased when combined with Nelfinavir. Approved, Investigational Macitentan The serum concentration of Macitentan can be increased when it is combined with Nelfinavir. Approved Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Nelfinavir. Approved, Investigational ME-609 The serum concentration of ME-609 can be increased when it is combined with Nelfinavir. Investigational Mebendazole The metabolism of Mebendazole can be decreased when combined with Nelfinavir. Approved, Vet Approved Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nelfinavir. Approved, Investigational Medrysone The serum concentration of Medrysone can be increased when it is combined with Nelfinavir. Approved Mefloquine The metabolism of Mefloquine can be decreased when combined with Nelfinavir. Approved, Investigational Melatonin The metabolism of Melatonin can be decreased when combined with Nelfinavir. Approved, Nutraceutical, Vet Approved Melengestrol The serum concentration of Melengestrol can be increased when it is combined with Nelfinavir. Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Nelfinavir. Approved, Vet Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Nelfinavir. Investigational, Withdrawn Meprobamate The metabolism of Meprobamate can be decreased when combined with Nelfinavir. Approved, Illicit Mestranol The serum concentration of Mestranol can be decreased when it is combined with Nelfinavir. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Nelfinavir. Experimental Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir. Approved Methadone The serum concentration of Methadone can be decreased when it is combined with Nelfinavir. Approved Methallenestril The serum concentration of Methallenestril can be decreased when it is combined with Nelfinavir. Experimental Methantheline The serum concentration of Nelfinavir can be decreased when it is combined with Methantheline. Approved, Investigational Methaqualone The metabolism of Methaqualone can be decreased when combined with Nelfinavir. Illicit, Withdrawn Methoxsalen The metabolism of Methoxsalen can be decreased when combined with Nelfinavir. Approved Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Methsuximide The metabolism of Methsuximide can be decreased when combined with Nelfinavir. Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nelfinavir. Approved Methylphenobarbital The metabolism of Methylphenobarbital can be decreased when combined with Nelfinavir. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Nelfinavir. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Nelfinavir. Approved Metiamide The serum concentration of Nelfinavir can be decreased when it is combined with Metiamide. Experimental Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Nelfinavir. Approved, Investigational Metronidazole The metabolism of Metronidazole can be decreased when combined with Nelfinavir. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Nelfinavir. Experimental Mexiletine The metabolism of Mexiletine can be decreased when combined with Nelfinavir. Approved, Investigational Mianserin The metabolism of Mianserin can be decreased when combined with Nelfinavir. Approved, Investigational Mibefradil The metabolism of Mibefradil can be decreased when combined with Nelfinavir. Investigational, Withdrawn Miconazole The metabolism of Miconazole can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Midazolam The serum concentration of Midazolam can be increased when it is combined with Nelfinavir. Approved, Illicit Midostaurin The metabolism of Midostaurin can be decreased when combined with Nelfinavir. Approved, Investigational Mifepristone The serum concentration of Nelfinavir can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Nelfinavir. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Nelfinavir. Approved Mirabegron The metabolism of Mirabegron can be decreased when combined with Nelfinavir. Approved Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Nelfinavir. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nelfinavir. Approved, Investigational Mitotane The serum concentration of Nelfinavir can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Moclobemide can be decreased when combined with Nelfinavir. Approved, Investigational Modafinil The metabolism of Modafinil can be decreased when combined with Nelfinavir. Approved, Investigational Mometasone The serum concentration of Mometasone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Montelukast The metabolism of Montelukast can be decreased when combined with Nelfinavir. Approved Morphine The metabolism of Morphine can be decreased when combined with Nelfinavir. Approved, Investigational Moxifloxacin Nelfinavir may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Nelfinavir. Approved, Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Nelfinavir. Approved Naloxone The metabolism of Naloxone can be decreased when combined with Nelfinavir. Approved, Vet Approved Nateglinide The metabolism of Nateglinide can be decreased when combined with Nelfinavir. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be increased when it is combined with Nelfinavir. Investigational Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Nelfinavir. Approved, Withdrawn Neratinib The metabolism of Neratinib can be decreased when combined with Nelfinavir. Approved, Investigational Netupitant The serum concentration of Nelfinavir can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Nevirapine resulting in a loss in efficacy. Approved Nicardipine The metabolism of Nicardipine can be decreased when combined with Nelfinavir. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Nelfinavir. Approved, Investigational Nicotine The metabolism of Nicotine can be decreased when combined with Nelfinavir. Approved Nifedipine The metabolism of Nifedipine can be decreased when combined with Nelfinavir. Approved Nilotinib The serum concentration of Nilotinib can be increased when it is combined with Nelfinavir. Approved, Investigational Nilutamide The metabolism of Nilutamide can be decreased when combined with Nelfinavir. Approved, Investigational Nilvadipine The metabolism of Nilvadipine can be decreased when combined with Nelfinavir. Approved, Investigational Nimodipine The serum concentration of Nimodipine can be increased when it is combined with Nelfinavir. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Nelfinavir. Approved Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir. Approved Nisoldipine The metabolism of Nisoldipine can be decreased when combined with Nelfinavir. Approved Nitrazepam The metabolism of Nitrazepam can be decreased when combined with Nelfinavir. Approved Nitrendipine The metabolism of Nitrendipine can be decreased when combined with Nelfinavir. Approved, Investigational Nizatidine The serum concentration of Nelfinavir can be decreased when it is combined with Nizatidine. Approved Norelgestromin The serum concentration of Norelgestromin can be decreased when it is combined with Nelfinavir. Approved, Investigational Norethisterone The metabolism of Norethisterone can be decreased when combined with Nelfinavir. Approved Norgestimate The serum concentration of Norgestimate can be decreased when it is combined with Nelfinavir. Approved, Investigational Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Nelfinavir. Approved Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Nelfinavir. Approved Odanacatib The metabolism of Odanacatib can be decreased when combined with Nelfinavir. Investigational Ofloxacin Nelfinavir may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine The serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine. Approved, Investigational Olaparib The serum concentration of Olaparib can be increased when it is combined with Nelfinavir. Approved Oleoyl-estrone The serum concentration of Oleoyl-estrone can be increased when it is combined with Nelfinavir. Investigational Olopatadine The metabolism of Olopatadine can be decreased when combined with Nelfinavir. Approved Omeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Omeprazole resulting in a loss in efficacy. Approved, Investigational, Vet Approved Ondansetron The metabolism of Ondansetron can be decreased when combined with Nelfinavir. Approved Opipramol The serum concentration of Opipramol can be increased when it is combined with Nelfinavir. Investigational Opium The metabolism of Opium can be decreased when combined with Nelfinavir. Approved, Illicit Orphenadrine The metabolism of Orphenadrine can be decreased when combined with Nelfinavir. Approved Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Nelfinavir. Approved Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Nelfinavir. Approved, Investigational Oxazepam The metabolism of Oxazepam can be decreased when combined with Nelfinavir. Approved Oxiconazole The metabolism of Oxiconazole can be decreased when combined with Nelfinavir. Approved Oxybutynin The serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Nelfinavir. Approved, Vet Approved Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Nelfinavir. Approved, Investigational Paliperidone Nelfinavir may increase the QTc-prolonging activities of Paliperidone. Approved Palonosetron The metabolism of Palonosetron can be decreased when combined with Nelfinavir. Approved, Investigational Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Nelfinavir. Approved, Investigational Pantoprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy. Approved Paramethadione The metabolism of Paramethadione can be decreased when combined with Nelfinavir. Approved Paramethasone The metabolism of Paramethasone can be decreased when combined with Nelfinavir. Approved Parecoxib The serum concentration of Parecoxib can be increased when it is combined with Nelfinavir. Approved Paricalcitol The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. Approved, Investigational Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Nelfinavir. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Nelfinavir. Approved Pentamidine The metabolism of Pentamidine can be decreased when combined with Nelfinavir. Approved, Investigational Pentobarbital The serum concentration of Pentobarbital can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Perampanel The metabolism of Perampanel can be decreased when combined with Nelfinavir. Approved Perflutren Nelfinavir may increase the QTc-prolonging activities of Perflutren. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Nelfinavir. Approved, Investigational, Vet Approved, Withdrawn Perhexiline The metabolism of Perhexiline can be decreased when combined with Nelfinavir. Approved, Investigational Permethrin The metabolism of Permethrin can be decreased when combined with Nelfinavir. Approved, Investigational Perospirone The metabolism of Perospirone can be decreased when combined with Nelfinavir. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Nelfinavir. Approved Pethidine The risk or severity of adverse effects can be increased when Nelfinavir is combined with Pethidine. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Nelfinavir. Withdrawn Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Nelfinavir. Approved, Investigational, Withdrawn Phenobarbital The serum concentration of Phenobarbital can be increased when it is combined with Nelfinavir. Approved, Investigational Phenoxybenzamine The metabolism of Phenoxybenzamine can be decreased when combined with Nelfinavir. Approved Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Nelfinavir. Approved, Investigational Phenytoin The serum concentration of Phenytoin can be decreased when it is combined with Nelfinavir. Approved, Vet Approved Pilocarpine The metabolism of Pilocarpine can be decreased when combined with Nelfinavir. Approved, Investigational Pimecrolimus The metabolism of Pimecrolimus can be decreased when combined with Nelfinavir. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Nelfinavir. Approved Pinacidil The metabolism of Pinacidil can be decreased when combined with Nelfinavir. Approved Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Nelfinavir. Approved, Investigational Piperaquine The metabolism of Piperaquine can be decreased when combined with Nelfinavir. Approved, Investigational Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Nelfinavir. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Nelfinavir. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Nelfinavir. Approved, Investigational Podofilox The metabolism of Podofilox can be decreased when combined with Nelfinavir. Approved Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Nelfinavir. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Nelfinavir. Approved, Investigational Posaconazole The metabolism of Posaconazole can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Nelfinavir. Approved, Investigational Pranlukast The serum concentration of Pranlukast can be increased when it is combined with Nelfinavir. Approved, Investigational Prasterone The metabolism of Prasterone can be decreased when combined with Nelfinavir. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be increased when it is combined with Nelfinavir. Investigational Prasugrel The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Pravastatin The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir. Approved Prazepam The metabolism of Prazepam can be decreased when combined with Nelfinavir. Approved, Illicit Praziquantel The metabolism of Praziquantel can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Prednicarbate The serum concentration of Prednicarbate can be increased when it is combined with Nelfinavir. Approved, Investigational Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be increased when it is combined with Nelfinavir. Approved, Experimental, Investigational Primaquine The metabolism of Primaquine can be decreased when combined with Nelfinavir. Approved Primidone The serum concentration of Primidone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Procainamide Nelfinavir may increase the QTc-prolonging activities of Procainamide. Approved Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Nelfinavir. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Nelfinavir. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Nelfinavir. Approved Promazine The metabolism of Promazine can be decreased when combined with Nelfinavir. Approved, Vet Approved Promethazine The serum concentration of Nelfinavir can be decreased when it is combined with Promethazine. Approved, Investigational Propafenone The serum concentration of Propafenone can be increased when it is combined with Nelfinavir. Approved Propofol The metabolism of Propofol can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Propoxyphene napsylate The metabolism of Propoxyphene napsylate can be decreased when combined with Nelfinavir. Approved Propranolol The metabolism of Propranolol can be decreased when combined with Nelfinavir. Approved, Investigational Protriptyline The serum concentration of Protriptyline can be increased when it is combined with Nelfinavir. Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Nelfinavir. Approved Pyrazinamide The metabolism of Pyrazinamide can be decreased when combined with Nelfinavir. Approved, Investigational Quazepam The metabolism of Quazepam can be decreased when combined with Nelfinavir. Approved, Illicit Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Nelfinavir. Approved Quinacrine The metabolism of Quinacrine can be decreased when combined with Nelfinavir. Approved, Investigational Quinidine The serum concentration of Quinidine can be increased when it is combined with Nelfinavir. Approved, Investigational Quinine The metabolism of Quinine can be decreased when combined with Nelfinavir. Approved Rabeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy. Approved, Investigational Raloxifene The metabolism of Raloxifene can be decreased when combined with Nelfinavir. Approved, Investigational Ramelteon The serum concentration of Ramelteon can be increased when it is combined with Nelfinavir. Approved, Investigational Ranitidine The serum concentration of Nelfinavir can be decreased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Nelfinavir. Approved, Investigational Reboxetine The metabolism of Reboxetine can be decreased when combined with Nelfinavir. Approved, Investigational Regorafenib The metabolism of Regorafenib can be decreased when combined with Nelfinavir. Approved Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Nelfinavir. Approved, Investigational Retapamulin The serum concentration of Retapamulin can be increased when it is combined with Nelfinavir. Approved Ribociclib The serum concentration of Ribociclib can be increased when it is combined with Nelfinavir. Approved, Investigational Rifabutin The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Nelfinavir. Approved, Investigational Rifampicin The serum concentration of Nelfinavir can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Rifapentine can be increased when it is combined with Nelfinavir. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Nelfinavir. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Nelfinavir. Approved Rimexolone The serum concentration of Rimexolone can be increased when it is combined with Nelfinavir. Approved Rimonabant The metabolism of Rimonabant can be decreased when combined with Nelfinavir. Approved, Investigational Riociguat The serum concentration of Riociguat can be increased when it is combined with Nelfinavir. Approved Risperidone The metabolism of Risperidone can be decreased when combined with Nelfinavir. Approved, Investigational Ritonavir The metabolism of Ritonavir can be decreased when combined with Nelfinavir. Approved, Investigational Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Nelfinavir. Approved Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Rolapitant The metabolism of Rolapitant can be decreased when combined with Nelfinavir. Approved, Investigational Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Nelfinavir. Approved, Investigational Ropinirole The metabolism of Ropinirole can be decreased when combined with Nelfinavir. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Nelfinavir. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nelfinavir. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Nelfinavir. Approved Rotigotine The metabolism of Rotigotine can be decreased when combined with Nelfinavir. Approved Roxatidine acetate The serum concentration of Nelfinavir can be decreased when it is combined with Roxatidine acetate. Approved, Investigational Roxithromycin The metabolism of Roxithromycin can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Rucaparib The metabolism of Rucaparib can be decreased when combined with Nelfinavir. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Nelfinavir. Approved Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir. Approved Safinamide The metabolism of Safinamide can be decreased when combined with Nelfinavir. Approved, Investigational Salmeterol The serum concentration of Salmeterol can be increased when it is combined with Nelfinavir. Approved Salmeterol The metabolism of Salmeterol can be decreased when combined with Nelfinavir. Approved Saquinavir The metabolism of Saquinavir can be decreased when combined with Nelfinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Nelfinavir can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Nelfinavir. Approved Selegiline The metabolism of Selegiline can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Selexipag The metabolism of Selexipag can be decreased when combined with Nelfinavir. Approved Seratrodast The metabolism of Seratrodast can be decreased when combined with Nelfinavir. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Sertraline The metabolism of Sertraline can be decreased when combined with Nelfinavir. Approved Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Nelfinavir. Approved, Vet Approved Sibutramine The metabolism of Sibutramine can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational, Withdrawn Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Nelfinavir. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Nelfinavir. Approved Siltuximab The serum concentration of Nelfinavir can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Nelfinavir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Nelfinavir. Approved Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Nelfinavir. Approved, Investigational Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Nelfinavir. Approved, Investigational Sofosbuvir The serum concentration of Sofosbuvir can be decreased when it is combined with Nelfinavir. Approved Solifenacin The metabolism of Solifenacin can be decreased when combined with Nelfinavir. Approved Sonidegib The serum concentration of Sonidegib can be increased when it is combined with Nelfinavir. Approved, Investigational Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Nelfinavir. Approved, Investigational Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Nelfinavir. Investigational Sotalol Nelfinavir may increase the QTc-prolonging activities of Sotalol. Approved Spiramycin The metabolism of Spiramycin can be decreased when combined with Nelfinavir. Approved St. John's Wort The metabolism of Nelfinavir can be increased when combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Nelfinavir can be increased when it is combined with Stiripentol. Approved Sufentanil The metabolism of Sufentanil can be decreased when combined with Nelfinavir. Approved, Investigational Sulfadiazine The metabolism of Sulfadiazine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Sulfamethoxazole can be decreased when combined with Nelfinavir. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Nelfinavir. Approved Sulfisoxazole The metabolism of Nelfinavir can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Nelfinavir. Approved, Investigational Sunitinib The metabolism of Sunitinib can be decreased when combined with Nelfinavir. Approved, Investigational Suvorexant The serum concentration of Suvorexant can be increased when it is combined with Nelfinavir. Approved, Investigational Synthetic Conjugated Estrogens, A The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nelfinavir. Approved Synthetic Conjugated Estrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nelfinavir. Approved Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Nelfinavir. Approved, Investigational Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Nelfinavir. Approved, Investigational Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Nelfinavir. Approved Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir. Approved, Investigational Tapentadol The metabolism of Tapentadol can be decreased when combined with Nelfinavir. Approved Tasimelteon The serum concentration of Tasimelteon can be increased when it is combined with Nelfinavir. Approved, Investigational Tasosartan The metabolism of Tasosartan can be decreased when combined with Nelfinavir. Approved Taurochenodeoxycholic acid The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nelfinavir. Experimental Telaprevir The metabolism of Telaprevir can be decreased when combined with Nelfinavir. Approved, Withdrawn Telavancin Nelfinavir may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin The metabolism of Telithromycin can be decreased when combined with Nelfinavir. Approved Temazepam The metabolism of Temazepam can be decreased when combined with Nelfinavir. Approved, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus. Approved Teniposide The metabolism of Teniposide can be decreased when combined with Nelfinavir. Approved Terbinafine The metabolism of Terbinafine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Nelfinavir. Approved, Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Nelfinavir. Experimental Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Nelfinavir. Investigational Testosterone The metabolism of Testosterone can be decreased when combined with Nelfinavir. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Nelfinavir. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Nelfinavir. Approved Testosterone propionate The metabolism of Testosterone propionate can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Nelfinavir. Approved, Investigational Tetrabenazine Nelfinavir may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetracycline The metabolism of Tetracycline can be decreased when combined with Nelfinavir. Approved, Vet Approved Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Nelfinavir. Approved, Investigational Thalidomide The metabolism of Thalidomide can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Theophylline The metabolism of Theophylline can be decreased when combined with Nelfinavir. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Nelfinavir. Approved, Withdrawn Thiotepa The metabolism of Thiotepa can be decreased when combined with Nelfinavir. Approved, Investigational Tiagabine The metabolism of Tiagabine can be decreased when combined with Nelfinavir. Approved, Investigational Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Nelfinavir. Approved, Investigational Ticagrelor The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Nelfinavir. Approved Timolol The metabolism of Timolol can be decreased when combined with Nelfinavir. Approved Tinidazole The metabolism of Tinidazole can be decreased when combined with Nelfinavir. Approved, Investigational Tiotropium The metabolism of Tiotropium can be decreased when combined with Nelfinavir. Approved Tipranavir The serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be increased when it is combined with Nelfinavir. Approved, Withdrawn Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Nelfinavir. Approved, Investigational Tocilizumab The serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab. Approved Tocopherol The metabolism of Tocopherol can be decreased when combined with Nelfinavir. Approved, Investigational Tofacitinib The serum concentration of Tofacitinib can be increased when it is combined with Nelfinavir. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Nelfinavir. Approved, Investigational Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Nelfinavir. Approved, Investigational Tolterodine The serum concentration of Tolterodine can be increased when it is combined with Nelfinavir. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Nelfinavir. Approved Topiramate The metabolism of Nelfinavir can be decreased when combined with Topiramate. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Nelfinavir. Approved, Investigational Toremifene The risk or severity of adverse effects can be increased when Nelfinavir is combined with Toremifene. Approved, Investigational Trabectedin The serum concentration of Trabectedin can be increased when it is combined with Nelfinavir. Approved, Investigational Tramadol The serum concentration of Tramadol can be increased when it is combined with Nelfinavir. Approved, Investigational Tranylcypromine The metabolism of Nelfinavir can be decreased when combined with Tranylcypromine. Approved, Investigational Trastuzumab emtansine The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Nelfinavir. Approved, Investigational Trazodone The serum concentration of Trazodone can be increased when it is combined with Nelfinavir. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Nelfinavir. Approved, Investigational, Nutraceutical Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Nelfinavir. Approved, Vet Approved Triazolam The serum concentration of Triazolam can be increased when it is combined with Nelfinavir. Approved, Investigational Trimethadione The metabolism of Trimethadione can be decreased when combined with Nelfinavir. Approved Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Nelfinavir. Approved, Vet Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Nelfinavir. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Nelfinavir. Investigational, Withdrawn Troleandomycin The metabolism of Troleandomycin can be decreased when combined with Nelfinavir. Approved Udenafil The metabolism of Udenafil can be decreased when combined with Nelfinavir. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Nelfinavir. Approved Ulobetasol The serum concentration of Ulobetasol can be increased when it is combined with Nelfinavir. Approved Valbenazine The metabolism of Valbenazine can be decreased when combined with Nelfinavir. Approved, Investigational Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be decreased when it is combined with Nelfinavir. Approved, Investigational Vandetanib The metabolism of Vandetanib can be decreased when combined with Nelfinavir. Approved Vanoxerine The metabolism of Vanoxerine can be decreased when combined with Nelfinavir. Investigational Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Nelfinavir. Approved Velpatasvir The metabolism of Velpatasvir can be decreased when combined with Nelfinavir. Approved, Investigational Vemurafenib The serum concentration of Vemurafenib can be increased when it is combined with Nelfinavir. Approved Venetoclax The metabolism of Venetoclax can be decreased when combined with Nelfinavir. Approved, Investigational Venlafaxine The metabolism of Venlafaxine can be decreased when combined with Nelfinavir. Approved Verapamil The metabolism of Verapamil can be decreased when combined with Nelfinavir. Approved Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Nelfinavir. Investigational Vilanterol The metabolism of Vilanterol can be decreased when combined with Nelfinavir. Approved Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Nelfinavir. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nelfinavir. Approved, Investigational Vinblastine The metabolism of Vinblastine can be decreased when combined with Nelfinavir. Approved Vincristine The serum concentration of Vincristine can be increased when it is combined with Nelfinavir. Approved, Investigational Vincristine The metabolism of Vincristine can be decreased when combined with Nelfinavir. Approved, Investigational Vindesine The serum concentration of Vindesine can be increased when it is combined with Nelfinavir. Approved, Investigational Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Nelfinavir. Approved, Investigational Vismodegib The metabolism of Vismodegib can be decreased when combined with Nelfinavir. Approved, Investigational Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Nelfinavir. Approved, Investigational Vorapaxar The serum concentration of Vorapaxar can be increased when it is combined with Nelfinavir. Approved Voriconazole The serum concentration of Nelfinavir can be increased when it is combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Nelfinavir. Approved, Investigational Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Nelfinavir. Approved, Investigational Warfarin The serum concentration of Warfarin can be decreased when it is combined with Nelfinavir. Approved Yohimbine The metabolism of Yohimbine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Nelfinavir. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Nelfinavir. Approved, Investigational Zaleplon The metabolism of Zaleplon can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Nelfinavir. Approved Zileuton The metabolism of Zileuton can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Nelfinavir. Approved Zolpidem The metabolism of Zolpidem can be decreased when combined with Nelfinavir. Approved Zomepirac The metabolism of Zomepirac can be decreased when combined with Nelfinavir. Withdrawn Zonisamide The metabolism of Zonisamide can be decreased when combined with Nelfinavir. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be increased when it is combined with Nelfinavir. Approved Zotepine The metabolism of Zotepine can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Nelfinavir can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir. Approved, Investigational - Food Interactions
- Food significantly increases absorption (2 to 3 times).
- Take with food.
References
- Synthesis Reference
- US5461154
- General References
- Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH: Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. [PubMed:9397180]
- External Links
- Human Metabolome Database
- HMDB0014365
- KEGG Drug
- D08259
- KEGG Compound
- C07257
- PubChem Compound
- 64143
- PubChem Substance
- 46507719
- ChemSpider
- 57718
- BindingDB
- 518
- ChEBI
- 7496
- ChEMBL
- CHEMBL584
- Therapeutic Targets Database
- DAP000705
- PharmGKB
- PA450606
- HET
- 1UN
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Nelfinavir
- ATC Codes
- J05AE04 — Nelfinavir
- AHFS Codes
- 08:18.08.08 — HIV Protease Inhibitors
- PDB Entries
- 1ohr / 2pym / 2pyn / 2q63 / 2q64 / 2qak / 2r5q / 3ekx / 3el0 / 3el5
- FDA label
- Download (294 KB)
- MSDS
- Download (56.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Agouron pharmaceuticals inc
- Packagers
- Agouron Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Cardinal Health
- Dept Health Central Pharmacy
- Dispensing Solutions
- Goedecke GmbH
- H.J. Harkins Co. Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Patheon Inc.
- PD-Rx Pharmaceuticals Inc.
- Pfizer Inc.
- Physicians Total Care Inc.
- Quality Care
- Remedy Repack
- St Mary's Medical Park Pharmacy
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Powder Oral 50 mg/g Tablet Oral 625 mg Tablet, film coated Oral 250 mg/1 Tablet, film coated Oral 625 mg/1 Tablet Oral 250 mg Powder Oral 50 mg - Prices
Unit description Cost Unit Viracept 625 mg tablet 11.24USD tablet Viracept 250 mg tablet 3.46USD tablet Viracept 50 mg/gm Powder 0.54USD gm DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5484926 No 1994-04-07 2014-04-07 US CA2173328 No 1999-08-31 2014-10-07 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 349.84 °C Not Available water solubility Slightly soluble Not Available logP 6 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00191 mg/mL ALOGPS logP 4.61 ALOGPS logP 4.72 ChemAxon logS -5.5 ALOGPS pKa (Strongest Acidic) 9.32 ChemAxon pKa (Strongest Basic) 8.18 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 101.9 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 162.67 m3·mol-1 ChemAxon Polarizability 63.8 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.7472 Blood Brain Barrier - 0.9659 Caco-2 permeable - 0.7148 P-glycoprotein substrate Substrate 0.9332 P-glycoprotein inhibitor I Inhibitor 0.8121 P-glycoprotein inhibitor II Inhibitor 0.7572 Renal organic cation transporter Non-inhibitor 0.8178 CYP450 2C9 substrate Non-substrate 0.7482 CYP450 2D6 substrate Substrate 0.8918 CYP450 3A4 substrate Substrate 0.7408 CYP450 1A2 substrate Non-inhibitor 0.9085 CYP450 2C9 inhibitor Non-inhibitor 0.7994 CYP450 2D6 inhibitor Non-inhibitor 0.8071 CYP450 2C19 inhibitor Non-inhibitor 0.6335 CYP450 3A4 inhibitor Inhibitor 0.5465 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8977 Ames test Non AMES toxic 0.8008 Carcinogenicity Non-carcinogens 0.8547 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4704 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9786 hERG inhibition (predictor II) Inhibitor 0.785
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- o-Toluamides / Piperidinecarboxamides / Benzamides / Thiophenol ethers / Ortho cresols / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Alkylarylthioethers / Trialkylamines show 9 more
- Substituents
- Alpha-amino acid amide / Piperidinecarboxamide / 2-piperidinecarboxamide / Toluamide / Benzamide / O-toluamide / Benzoic acid or derivatives / Thiophenol ether / O-cresol / Benzoyl show 31 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- tertiary amino compound, secondary alcohol, aryl sulfide, phenols, benzamides, organic heterobicyclic compound (CHEBI:7496)
Targets
- Kind
- Protein
- Organism
- Human immunodeficiency virus
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Aspartic-type endopeptidase activity
- Specific Function
- Not Available
- Gene Name
- HIV-1 protease
- Uniprot ID
- O90777
- Uniprot Name
- HIV-1 protease
- Molecular Weight
- 10724.61 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027]
- Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388]
- Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694]
- Perez MA, Fernandes PA, Ramos MJ: Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead. J Mol Graph Model. 2007 Oct;26(3):634-42. Epub 2007 Mar 24. [PubMed:17459746]
- Velazquez-Campoy A, Kiso Y, Freire E: The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys. 2001 Jun 15;390(2):169-75. [PubMed:11396919]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100-2. [PubMed:11159797]
- Tanabe M, Hashimoto M, Ono H: Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. Eur J Pharmacol. 2008 Jul 28;589(1-3):102-5. doi: 10.1016/j.ejphar.2008.06.013. Epub 2008 Jun 7. [PubMed:18602099]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459]
- Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitorInducer
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301]
- Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
- Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94. [PubMed:9435299]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM: Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34. [PubMed:10681378]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 00:54